Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury
Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury
复制标题
DOI：
10.1021/tx049904e
复制
发表时间：
2004-08-01
影响因子：
4.1
通讯作者：
Pickering, IJ
中科院分区：
文献类型：
--
作者：
George, GN;Prince, RC;Pickering, IJ
汞中毒的临床螯合治疗通常使用两种药物中的一种或两种-中位二硫代丁二酸(DMSA)和二硫代丙磺酸(DMPS)，商业上分别以Chemet和Dimaval的名称出售。我们使用了汞的L-III边缘X射线吸收光谱和密度泛函理论计算相结合的方法，研究了汞离子与这些螯合治疗药物相互作用的化学。我们表明，DMSA和DMPS都不能与汞离子形成真正的络合物，这些药物应该被认为是结合汞离子的临床任务的次佳药物。我们讨论了汞特定的螯合剂分子或“定制螯合剂”的设计标准，这可能形成改进的临床治疗的基础。
Clinical chelation therapy of mercury poisoning generally uses one or both of two drugs-meso-dimercaptosuccinic acid (DMSA) and dimercaptopropanesulfonic acid (DMPS), commercially sold as Chemet and Dimaval, respectively. We have used a combination of mercury L-III-edge X-ray absorption spectroscopy and density functional theory calculations to investigate the chemistry of interaction of mercuric ions with each of these chelation therapy drugs. We show that neither DMSA nor DMPS forms a true chelate complex with mercuric ions and that these drugs should be considered suboptimal for their clinical task of binding mercuric ions. We discuss the design criteria for a mercuric specific chelator molecule or "custom chelator", which might form the basis for an improved clinical treatment.